Partial
Mostly Aligned
Patient Risk:
Medium
Summary
Claims about Symproic (indication, mechanism, and once-daily dosing) are largely aligned with the provided label excerpts, but many counseling/comparative and Movantik-specific claims cannot be supported because Movantik labeling is not included in the available sections. Several Symproic counseling items (empty-stomach/diarrhea/time-to-improvement) are also not supported by the provided excerpts.
Category Scores
Accurate Statements
Symproic (naldemedine) is an oral prescription medicine used to treat opioid-induced constipation (OIC) in adults.
Supported by 1 INDICATIONS AND USAGE and 2 DOSAGE AND ADMINISTRATION (2.2) excerpts.
Symproic works by blocking opioid effects in the gut.
Supported by 12.1 Mechanism of Action (peripherally acting mu-opioid receptor antagonist in GI tissues).
Symproic is taken once daily.
Supported by 2 DOSAGE AND ADMINISTRATION (2.2): 0.2 mg orally once daily with or without food.
Opioid antagonists can be contraindicated or require caution in some patients with certain severe gastrointestinal disease scenarios.
Supported by 4 CONTRAINDICATIONS and 5.1 Gastrointestinal Perforation (risk conditions; contraindicated in known/suspected obstruction; consider risk-benefit in conditions impairing GI integrity such as Crohn's disease).
Patients should clarify whether they have any history of bowel obstruction or severe GI disease.
Supported by 4 CONTRAINDICATIONS and 5.1 GI perforation risk/contraindication language.
Patients should clarify what other medicines they take that could affect safety.
Supported by 7 DRUG INTERACTIONS (Table 3 includes clinically important interactions and interventions).
Unsupported Statements
Movantik (naloxegol) is an oral prescription medicine used to treat opioid-induced constipation (OIC) in adults.
Movantik label information is not included in the provided available label sections.
Movantik works by blocking opioid effects in the gut.
Movantik mechanism not supported because Movantik label sections are not provided.
Movantik does not reverse pain relief from opioids.
No Movantik labeling provided in available sections to support this statement.
Movantik is taken once daily in typical use.
No Movantik dosing/timing information provided in available sections.
The exact timing instructions for Movantik, including whether it should be taken on an empty stomach, can differ by product label guidance.
Movantik label sections are not provided; no empty-stomach or timing instructions are available to evaluate.
Both Symproic and Movantik are intended for patients who take opioids for chronic pain.
Symproic population is partially supported, but Movantik portion is not verifiable due to missing Movantik labeling in provided sections.
Diarrhea is a frequent side effect for both Symproic and Movantik.
The provided excerpts do not establish diarrhea as a frequent adverse reaction for either product; only diarrhea appears as part of an opioid withdrawal symptom cluster for Symproic (5.2). Movantik label is not provided.
The pattern and severity of side effects from Symproic and Movantik can vary from person to person.
No such statement is present in the provided label excerpts, and Movantik labeling is not provided.
There is no single universally 'better' choice between Symproic and Movantik based only on brand names.
No comparative or selection guidance between products is provided in the available label excerpts.
Switching between Symproic and Movantik is common when one option causes troublesome diarrhea or cramps.
No switching guidance is provided in available label excerpts; Movantik labeling is not provided.
Switching between Symproic and Movantik is common when symptoms do not improve enough.
No switching or inadequate-response guidance is provided in available label excerpts; Movantik labeling is not provided.
Switching between Symproic and Movantik is common when dosing/timing fits a patient's routine better.
No switching guidance is provided in available label excerpts; Movantik labeling is not provided.
Patients should clarify whether they should take the dose on an empty stomach per label instructions.
For Symproic, the provided label excerpt states can be taken with or without food (2.2); empty-stomach clarification is not supported. Movantik portion is not auditable due to missing Movantik labeling.
Patients should clarify how soon they should expect constipation improvement.
No time-to-improvement counseling or expected onset is provided in the available label excerpts.
Patients should clarify what to do if they get diarrhea.
While diarrhea is mentioned as part of opioid withdrawal symptom cluster (5.2), the provided excerpts do not include specific patient instructions for diarrhea.
Contradictions
Low
AI Statement
Patients should clarify whether they should take the dose on an empty stomach per label instructions.
Label Reference
2 DOSAGE AND ADMINISTRATION (2.2) for SYMPROIC states 0.2 mg orally once daily with or without food.
Important Omissions
Movantik-specific safety and administration counseling should be limited/omitted because Movantik FDA-approved label content is not present in the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Some statements are not supported by the provided label excerpts (notably multiple Movantik claims and counseling items about empty stomach, diarrhea management, and expected improvement), and one Symproic-related counseling statement is inconsistent with the excerpt that SYMPROIC can be taken with or without food.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Many Movantik claims and multiple counseling/side-effect specificity statements are unsupported because Movantik labeling is not included in the provided available sections; additionally, an empty-stomach counseling statement conflicts with the SYMPROIC dosing excerpt (with or without food).
Suggested Improvement
Limit claims to SYMPROIC-only label-supported content from the provided excerpts; remove or qualify Movantik-specific statements, and replace unsupported counseling (empty stomach, time-to-improvement, and what to do for diarrhea) with label-supported information (e.g., SYMPROIC can be taken with or without food; GI perforation monitoring/discontinuation and contraindication/risk-benefit guidance).